CEROW: the cash flow

Cash Flow Overview

Unit: Dollar

Positive Cash Flow Breakdown

Negative Cash Flow Breakdown

Cash Flow

2026-06-30

2026-03-31

2025-12-31

2025-09-30

Net loss

-1,028,830

-5,885,914

-4,540,621

-4,856,395

Net loss

-5,885,914

-4,540,621

-4,856,395

Gain on revaluation of earnout liability

-19,500

Depreciation expense

61,699

67,304

69,354

Write off of deferred offering costs

500,000

Stock-based compensation

1,617,455

259,666

348,116

Gain from settlement of liabilities with vendors

Amortization of right-to-use operating lease asset

214,443

208,832

203,412

Gain from settlement of liabilities with vendors

Write off of deferred offering costs

105,419

500,000

Inducement expense

Stock-based compensation

2,739,540

Amortization of debt discount

136,765

Stock-based inducement expense-Successor

Inducement expense

863,550

Amortization of right-to-use operating lease asset

434,632

Gain on revaluation of earnout and derivative liabilities

Foreign currency transaction gain included in other income (expenses)

173

248

Foreign currency transaction gain included in other expenses, net

121

Net cash used in operating activities

-2,761,057

-3,806,433

-3,205,115

Derivative expense

-896,722

Loss on initial and revaluation of derivative liabilities

-4,000,255

Proceeds from sale of equity securities

500,000

Prepaid expenses and other current assets

-106,471

-354,991

540,073

257,078

Net cash provided by investing activities

500,000

Accounts payable

530,041

105,955

503,557

1,426,446

Proceeds from exercise of series a preferred warrants

Accrued liabilities

-15,779

136,977

23,120

-428,658

Proceeds from share purchases under eloc, net of issuance costs

456,166

5,155,645

Insurance financing liability

-180,536

-142,950

338,279

Proceeds from share purchases and collection of stock subscription receivables under eloc, net of issuance costs

1,278,217

Proceeds received from sale of series d preferred stock, net of issuance costs

2,560,981

Operating lease liability

-243,272

-237,527

-231,916

-644,476

Proceeds received from sale of series d preferred stock

2,560,981

Proceeds received from sale of series e preferred stock, net of issuance costs

1,926,133

Proceeds from collection of stock subscriptions receivable

Depreciation expense

-94,868

215,069

Proceeds received from sale of common stock and warrants, net of issuance costs

Amortization of debt discount

609,882

136,765

Proceeds received from sale of pre-funded warrants, net of issuance costs

Gain on revaluation of preferred stock liabilities

-6,610,240

Payment of deferred offering costs

174,505

Gain on revaluation of earnout liability

-19,500

Proceeds from exercise of pre-funded warrants

Inducement expense

Cash redemption of series c preferred stock

Net cash used in operating activities

-5,088,959

Payment of offering costs

105,419

Proceeds from share purchases under eloc, net of issuance costs

700,491

Proceeds from issuance of series a preferred stock, net of issuance costs

Proceeds from convertible notes, net

2,163,600

1,500,000

Advances from shareholder

Proceeds from exercise of series a preferred warrants

Payment of sponsor loans

Proceeds received from sale of series d preferred stock, net of issuance costs

Proceeds from short term borrowings, net

Proceeds received from sale of common stock and warrants

Payments for short term borrowings

Proceeds received from sale of pre-funded warrants, net of issuance costs

Proceeds received from sale of series b preferred stock

Proceeds received from sale of series b preferred stock, net of issuance costs

Proceeds from exercise of pre-funded warrants

Proceeds received from sale of series c preferred stock, net of issuance costs of 434,428

-2,240,180

Proceeds received from sale of series c preferred stock, net of issuance costs

Cash redemption of series c preferred stock

Net cash provided by financing activities

2,407,925

1,956,166

3,446,741

10,468,829

Net (decrease) increase in cash, restricted cash and cash equivalents

-804,891

-359,692

-1,280,602

Net decrease in cash, restricted cash and cash equivalents

-724,868

Cash, restricted cash and cash equivalents at beginning of period

857,489

1,662,380

2,022,072

3,327,060

Cash, restricted cash and cash equivalents at end of period

937,512

Cash and cash equivalents

862,756

Restricted cash

74,756

Cash, restricted cash and cash equivalents

937,512

857,489

1,662,380

2,022,072

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow Overview

Unit: Dollar

Positive Cash Flow Breakdown

Negative Cash Flow Breakdown

Cash Flow

2026-06-30

2026-03-31

2025-12-31

2025-09-30

Net loss

-1,028,830

-5,885,914

-4,540,621

-4,856,395

Net loss

-5,885,914

-4,540,621

-4,856,395

Gain on revaluation of earnout liability

-19,500

Depreciation expense

61,699

67,304

69,354

Write off of deferred offering costs

500,000

Stock-based compensation

1,617,455

259,666

348,116

Gain from settlement of liabilities with vendors

Amortization of right-to-use operating lease asset

214,443

208,832

203,412

Gain from settlement of liabilities with vendors

Write off of deferred offering costs

105,419

500,000

Inducement expense

Stock-based compensation

2,739,540

Amortization of debt discount

136,765

Stock-based inducement expense-Successor

Inducement expense

863,550

Amortization of right-to-use operating lease asset

434,632

Gain on revaluation of earnout and derivative liabilities

Foreign currency transaction gain included in other income (expenses)

173

248

Foreign currency transaction gain included in other expenses, net

121

Net cash used in operating activities

-2,761,057

-3,806,433

-3,205,115

Derivative expense

-896,722

Loss on initial and revaluation of derivative liabilities

-4,000,255

Proceeds from sale of equity securities

500,000

Prepaid expenses and other current assets

-106,471

-354,991

540,073

257,078

Net cash provided by investing activities

500,000

Accounts payable

530,041

105,955

503,557

1,426,446

Proceeds from exercise of series a preferred warrants

Accrued liabilities

-15,779

136,977

23,120

-428,658

Proceeds from share purchases under eloc, net of issuance costs

456,166

5,155,645

Insurance financing liability

-180,536

-142,950

338,279

Proceeds from share purchases and collection of stock subscription receivables under eloc, net of issuance costs

1,278,217

Proceeds received from sale of series d preferred stock, net of issuance costs

2,560,981

Operating lease liability

-243,272

-237,527

-231,916

-644,476

Proceeds received from sale of series d preferred stock

2,560,981

Proceeds received from sale of series e preferred stock, net of issuance costs

1,926,133

Proceeds from collection of stock subscriptions receivable

Depreciation expense

-94,868

215,069

Proceeds received from sale of common stock and warrants, net of issuance costs

Amortization of debt discount

609,882

136,765

Proceeds received from sale of pre-funded warrants, net of issuance costs

Gain on revaluation of preferred stock liabilities

-6,610,240

Payment of deferred offering costs

174,505

Gain on revaluation of earnout liability

-19,500

Proceeds from exercise of pre-funded warrants

Inducement expense

Cash redemption of series c preferred stock

Net cash used in operating activities

-5,088,959

Payment of offering costs

105,419

Proceeds from share purchases under eloc, net of issuance costs

700,491

Proceeds from issuance of series a preferred stock, net of issuance costs

Proceeds from convertible notes, net

2,163,600

1,500,000

Advances from shareholder

Proceeds from exercise of series a preferred warrants

Payment of sponsor loans

Proceeds received from sale of series d preferred stock, net of issuance costs

Proceeds from short term borrowings, net

Proceeds received from sale of common stock and warrants

Payments for short term borrowings

Proceeds received from sale of pre-funded warrants, net of issuance costs

Proceeds received from sale of series b preferred stock

Proceeds received from sale of series b preferred stock, net of issuance costs

Proceeds from exercise of pre-funded warrants

Proceeds received from sale of series c preferred stock, net of issuance costs of 434,428

-2,240,180

Proceeds received from sale of series c preferred stock, net of issuance costs

Cash redemption of series c preferred stock

Net cash provided by financing activities

2,407,925

1,956,166

3,446,741

10,468,829

Net (decrease) increase in cash, restricted cash and cash equivalents

-804,891

-359,692

-1,280,602

Net decrease in cash, restricted cash and cash equivalents

-724,868

Cash, restricted cash and cash equivalents at beginning of period

857,489

1,662,380

2,022,072

3,327,060

Cash, restricted cash and cash equivalents at end of period

937,512

Cash and cash equivalents

862,756

Restricted cash

74,756

Cash, restricted cash and cash equivalents

937,512

857,489

1,662,380

2,022,072

Time Plot

Show the time plot by selecting a row from the table.